

## SPEAKERS

- **Jesús Blázquez.** Spanish National Research Council (CSIC), Institute of Biomedicine of Seville. Seville, Spain
- **Germán Bou.** Department of Clinical Microbiology, University Hospital A Coruña (CHUAC)/Institute of Biomedical Research of A Coruña (INIBIC). A Coruña, Spain
- **Rafael Cantón.** Service of Microbiology. University Hospital Ramón y Cajal. Madrid, Spain
- **José Miguel Cisneros.** Department of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital V. del Rocío/Institute of Biomedicine of Seville. Seville, Spain
- **Felipe Fernández-Cuenca.** Department of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital Virgen Macarena/Institute of Biomedicine of Seville. Seville, Spain
- **Lorena López-Cerero.** Department of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital Virgen Macarena/Institute of Biomedicine of Seville. Seville, Spain
- **Luis Martínez.** Department of Clinical Microbiology, University Hospital Marqués de Valdecilla. Santander, Spain
- **Ferran Navarro.** Department of Clinical Microbiology, University Hospital Santa Creu i Sant Pau. Barcelona, Spain
- **Patrice Nordmann.** Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science, University of Fribourg. Fribourg, Switzerland.
- **Antonio Oliver.** Department of Clinical Microbiology, University Hospital Son Espases, University of the Illes Balears. Palma de Mallorca, Spain
- **Jerónimo Pachón.** Department of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital V. del Rocío/Institute of Biomedicine of Seville, University of Seville. Seville, Spain
- **Jose Ramón Paño Pardo.** Department of Infectious Diseases, University Hospital Lozano Blesa. Zaragoza, Spain
- **Álvaro Pascual.** Department of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital Virgen Macarena/Institute of Biomedicine of Seville, University of Seville. Seville, Spain
- **María Pérez-Vázquez.** National Center for Microbiology, National Health Institute Carlos III. Madrid, Spain
- **Jesús Rodríguez Baño.** Department of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital Virgen Macarena/Institute of Biomedicine of Seville, University of Seville. Seville, Spain
- **Harald Seifert.** Department of Medical Microbiology, Immunology and Hygiene. University Hospital, Cologne, Germany
- **Julián de la Torre.** Department of Infectious Diseases, University Hospital Reina Sofía/Institute Maimónides of Biomedical Research (IMIBIC), University of Córdoba. Córdoba, Spain
- **Raquel Valencia.** Department of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital Virgen del Rocío, University of Seville. Seville, Spain
- **Salvador Vergara.** Department of Microbiology and Infectious Diseases, Valme University Hospital. Seville, Spain

## SCIENTIFIC COMMITTEE

- **Jesús Blázquez.** Spanish National Research Council (CSIC), Institute of Biomedicine of Seville. Seville, Spain
- **José Miguel Cisneros.** Department of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital V. del Rocío/Institute of Biomedicine of Seville. Seville, Spain
- **Jerónimo Pachón.** Department of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital V. del Rocío/Institute of Biomedicine of Seville, University of Seville. Seville
- **Álvaro Pascual.** Department of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital Virgen Macarena/Institute of Biomedicine of Seville, University of Seville. Seville
- **Jesús Rodríguez Baño.** Department of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital Virgen Macarena/Institute of Biomedicine of Seville, University of Seville. Seville, Spain

## TOPICS

1. Epidemiology of carbapenemase-producing Gram-negative bacilli
2. Epidemiological basis from a molecular perspective
3. Health impact and clinical investigation of carbapenemases producing Gram-negative bacilli
4. New molecular tools for studying carbapenem-resistance
5. Relationship between carbapenemases and virulence
6. Therapeutic alternatives for carbapenem-resistant Gram-negative bacilli
7. Infection prevention and control measures

## PARTICIPANTS

- Health system professionals
- Researchers
- Scientists interested in infections caused by multidrug-resistant bacteria

## SPONSORS



Campus del Hospital Universitario Virgen del Rocío  
Avda. Manuel Siurot s/n • 41013 Sevilla  
Tel. +34 955 923 001 • Fax +34 955 923 101  
itribis@itribis.us.es  
www.itribis.ibis-sevilla.es




## WORKSHOP

“GLOBAL SPREAD OF  
CARBAPENEMASE-  
PRODUCING  
GRAMNEGATIVE  
BACILLI:  
A MAJOR CHALLENGE  
FOR TREATMENT AND  
INFECTION CONTROL”

Seville  
January 19<sup>th</sup> and 20<sup>th</sup>  
2016


Salón de Actos del IBIS  
Campus H. U. Virgen del Rocío





## WORKSHOP

“GLOBAL SPREAD OF CARBAPENEMASE-PRODUCING GRAMNEGATIVE BACILLI: A MAJOR CHALLENGE FOR TREATMENT AND INFECTION CONTROL”



## BACKGROUND

Antimicrobial resistance is reaching pandemic levels in the world, endangering the efficacy of our therapeutic armamentarium. The lack of pharmaceutical companies investment in the discovery of new molecules with antibiotic activity complicates, even more, the problem. These points have been recognized by all relevant national and international Health organizations. The fight against bacterial antimicrobial resistance is an European Union priority, which has launched different initiatives in this field, including *Joint Programme Initiative on Antimicrobial Resistance* (JPI-AMR), *Innovative Medicines Initiative* (IMI), *New Drugs for Bad Bugs* (ND4BB), *European Gram-negative Antibacterial Engine* (ENABLE), and *Combating Bacterial Resistance in Europe* (COMBACTE) (John H. Rex. ND4BB: addressing the antimicrobial resistance crisis. *Nature Rev Microbiol*-publishedonline; doi:10.1038/nrmicro3245; www.nature.com/nrmicro/journal/v12/n4/nrmicro3245/metrics).

Among the mechanisms of resistance in Gram-negative bacilli, carbapenemases are outstanding in terms of dissemination throughout the world, with increasing risk for the human health, multidrug-resistance in bacteria producing these enzymes and poor clinical outcomes. This topic, focused in *Enterobacteriaceae*, has been recently addressed by the European Centers for Disease Control and Prevention, both in terms of the knowledge of the problem - Carbapenemase-producing bacteria in Europe: carbapenemase-producing *Enterobacteriaceae* (EuSCAPE) project 2013 - and control Systematic review of the effectiveness of infection control measures to prevent the transmission of carbapenemase-producing *Enterobacteriaceae* through cross-border transfer of patients 2014.

# agenda

## DAY 1

10:00-11:00 **Registration**

11:00-11:15 **Presentation**

Jesús Blázquez (Seville)

11.15-12:00 **Opening Conference**

Emergence of carbapenemase producers: here is the storm.

Patrice Nordmann (Fribourg, Switzerland)

### Session 1. Global Epidemiology

Chairman: Jerónimo Pachón (Seville)

12:00-12:30 Evolution of carbapenemase-producing *Enterobacteriaceae* (CPE): a Spanish overview. María Pérez-Vázquez (Madrid)

12:30-13:00 Role of high risk clones of *Enterobacteriaceae* in the dissemination of carbapenemases. Lorena López-Cerero (Seville)

13:00-13:30 CPE dissemination in Andalusia. Felipe Fernández-Cuenca (Seville)

13:30-15:00 Lunch

### Session 2. Detection of carbapenemase producing *Enterobacteriaceae* in the clinical microbiology laboratory

Chairman: Álvaro Pascual (Seville)

15:00-15:30 Conventional detection of CPE in the clinical microbiology laboratory.

Luis Martínez (Santander)

15:30-16:00 Susceptibility of CPE: do the breakpoints matter?. Rafael Cantón (Madrid)

16:00-16:30 Coffee break

### Session 3. A molecular perspective and virulence

Chairman: Jesus Blázquez (Seville)

16:30-17:00 Genetic mobile elements and carbapenemases: who was first?

Ferran Navarro (Barcelona)

17:00-17:30 Virulence and carbapenemase production in *Enterobacteriaceae*.

German Bou (A Coruña)

21:00 Dinner

## DAY 2

### Session 4. Health impact

Chairman: Alvaro Pascual (Seville)

9:00-9:30 What happens in a hospital when an outbreak of CPE occurs?.

José Ramón Paño (Zaragoza)

9:30-10:00 CPE-related impact on outcomes. José Miguel Cisneros (Seville)

10:00-10:30 Coffee break

### Session 5. Therapeutic approaches

Chairman: José Miguel Cisneros (Seville)

10:30-11:00 Current treatment of infections caused by CPE: same solution for all carbapenemases? Jesús Rodríguez Baño (Seville)

11:00-11:30 New alternatives for the treatment of CPE infections.

Julián de la Torre (Córdoba)

### Session 6. Role of carbapenemases in other Gram negative bacteria

Chairman: Germán Bou (A Coruña)

11:30-12:00 Carbapenem-resistance and carbapenemases in *Pseudomonas aeruginosa*. Antonio Oliver (Palma de Mallorca)

12:00-12:30 Carbapenem-resistant *Acinetobacter baumannii*: role of carbapenemases. Harald Seifert (Cologne, Germany)

12:30-14:00 Lunch

### Session 7. Prevention and control

Chairman: Jesús Rodríguez Baño (Seville)

14:00-14:30 Control strategies for CPE in both the community and hospital setting. Raquel Valencia (Seville)

14:30-15:00 Role of environment in the dissemination of CPE. Salvador Vergara (Seville)

15:30-16:00 **Closing Remarks and Farewell**

Jerónimo Pachón (Seville)